RESEARCH ABSTRACTS
ABCG2 Hyperexpression in Large B-Cell Lymphoma of Immune-Privileged
Sites: A Crucial Mediator of Chemoresistance and Its Interface with MAPK
Pathway – A Prospective Target for Neoadjuvant Therapy.
Lab. Invest. March 2024, Vol 104 (3) (Supplement) : S1504.
Exploring the Molecular Landscape of Large B-cell lymphoma of Immune
privileged
Preliminary Insights into Phosphodiesterase 4 expression
and Potential Therapeutic Directions.
Lab. Invest. March 2024, Vol 104 (3) (Supplement) : S1502.
Cytogenetically Normal Acute Myeloid Leukaemia (CN-AML): Favourable
Prognosis of NPM1 Mutation may have Linkage with High Expression of
HOXA and PBX3 Genes.
Lab. Invest. March 2023. Vol 103 (3 ) (suppl): S-1085 (Abstract # 1065)
Cytogenetically Normal Acute Myeloid Leukaemia (CN-AML) in Young Adults:
HighExpression of ATM serine/threonine kinase (ATM) Gene has Prognostic
Implications.
Lab. Invest. March 2023 Vol 103 (3 ) (supplt ): S-1164, (abstract # 1030.)
Expression of CD47 Protein in Hematolymphoid Neoplasms: Implications for
CD47-Mediated Cancer Immunotherapy.
Mod Pathol. March 2022 Vol 35, 1016–1162 (Abstract # 971)
Prognostic Implications of NOTCH1 Pathway Activation Through
Transforming GrowthFactor-B (TGF-Beta ) / SETBP1 in Childhood Acute
Myeloid Leukemia (AML); Report of a Pilot Study.
Mod Pathol. March 2021. Vol 34, (Supplement 2): 927–1049. (Abstract # 682)
Plasmablastic Lymphoma (PBL): Crosstalk Between Overexpressed
Transforming Growth Factor Beta (TGFB ) Pathway Molecules with The Wnt/
Beta-Catenin Pathway May Identify Potential Therapeutic Targets.
Mod Pathol. March 2021. Vol 34, (Supplement 2): 927–1049. (Abstract # 710)
Overexpression of Histone Deacetylase 6 (HDAC6) Impedes the Survival of
Acute Myeloid Leukemia (AML) in Older Patients in Association with K-Ras
Effector Molecules.
Mod Pathol. March 2021. Vol 34, (Supplement 2): 927–1049. (Abstract # 735)
Acute Myeloid Leukaemia in Elderly: Extensive Expression Analysis of DNA
Damage Response (DDR) and Anti-Apoptosis Genes Identify Novel Targets for
Potential “Synergistic Lethality”.
Blood. November 2020. Vol 136 (Supplement 1):S39
Plasmablastic Lymphoma: Synergism between Wnt/B-Catenin and the RAS
Signalling Molecules May Identify Potential Targets for Therapy.
Blood. November 2020. Vol136 (Supplement 1):S36
“Losing the Brakes” - Suppressed Inhibitors are Another Possible Mechanism
of Uncontrolled Wnt Signaling in Old Age AML and a Potential for Targeted
Therapy.
Modern Pathology. 2020; 33 (suppl 2): 1247 (Abstract #1321)
Wnt/β-catenin Signaling in Plasmablastic Lymphoma (PBL) Remains “In
Check” through High Expression of Wnt/β-catenin Inhibitors.
Modern Pathology. 2020; 33 (suppl 2):1246. (Abstract # 1320)
Canadian Harmonization of Hans’ Algorithm for Diffuse Large B-Cell
Lymphoma (DLBCL); Aligning Analytical Sensitivity with Pathologist's
Readout Significantly Improves Diagnostic Accuracy.
Modern Pathology. 2020; 33 (suppl 2):1398-1399 (Abstract #1482)
Differential Expression of Immunity Related Genes Can Predict Moderate-
Severe Chronic GvHD Early after Myeloblative Hematopoietic Stem Cell
Transplantation.
Biology of Blood and Marrow Transplantation. 2019 Mar 01;25 (3 suppl):S237
Differential expression of DNA damage response (DDR) genes between
Follicular lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLCBL).
Modern Pathology. 2019 mar 01;32(Suppl 2):3 (Abstract #1237)
Un-regulation of the MYD88 Toll-like receptor B-cell receptor (MY-T-BCR)
Super complex and mTOR Signaling Axis in Primary Testicular Diffuse Large
B-cell Lymphoma.
Modern Pathology. 2019 Mar 18;32(Suppl 2):151 (Abstract #1402)
Metabolomics Profiling of Follicular Lymphoma: A Proof-of-Principle Study.
Modern Pathology, 2018, Vol. 31 (Supl 2): 537 (Abstract #1507).
Dysregulation of micrornas-mRNAs expression and their potential therapeutic
targets in acute promyelocytic leukaemia.
Experimental Hematology, September 2017 Vol 53 (Supplement): S97
PO27 FCGRIIA Gene Variant Influences Differential Rituximab Mediated NK
Cell Response Against Different B-Cell Lymphoma Targets.
Human Immunology. September 2017; Vol 78 (Supplement):1-266.
Gene Expression Signaling Signature Provides Insights into Poor Survival
Associated with High Expression of BRIC5 (Survivin) in Mantle Cell
Lymphoma.
Modern Pathol. 2016.29 (S2): 343A
Objective Quantification of BCL2 by Immunofluorescence in Routine Biopsy
Samples Predicts Response to R-CHOP and Overall Survival in Diffuse Large
B-Cell Lymphoma.
Modern Pathol.2016.29 (S2): 359A
Differential Gene Expression Using RNA Sequencing Between Elderly Acute
Myeloid Leukemia (AML) Patients with Long Versus Short-Term Survival.
Blood. Dec. 2016. Vol 128 (Issue 2): 1683 (Abstract # 617)
A bio clinical prognostic model incorporating MYC and BCL2 predicts
outcome to salvage therapy in relapsed/refractory diffuse large B-cell
lymphoma: An NCIC CTG LY12 Correlative science study.
Haematologica. June, 2016. Vol. 101 No ( Supplement S1)
Gene-Expression for Prediction of Disease Progression Following Initial
Management of Follicular Lymphoma.
Blood. December 2015. Vol 126 (Issue 23) (Supplement 3): 4804
Morphologic Evolution in Post-Transparent Lymphoproliferative Disorders
(PTLD): A Clinicopathologic Case Series.
Blood December 2015. Vol 126 (Issue 3)(Supplemen):5008
Digital Fusion-Gene expression profiling in acute leukemia (AL): Clinical
validation of throughput molecular technology in laboratory medicine.
J Clin Oncol . 2015; 33 (suppl) ( abstract # 7066)
Relationship of distinct B-cell receptor (BCR) isotype in diffuse large b-cell
lymphoma (DLBCL) with ABC and GCB genetic signatures and association
with signaling molecules of clinical significance.
J Clin Oncol. 2015; 33 (suppl) ( abstract # 8568)
Plasmablastic Lymphoma. Gene expression profile data related to NF-KB
pathways provides insights into clinical utility of proteasome inhibitor
(Bortezomib).
Modern Pathology. 2015 (2):574A
"Mantle cell lymphoma: Toll-like receptors (TLRs) and B-cell receptor (BCR)
gene expression analysis identify a distinct BCR activated subset, with
germinal center signature and indolent biology".
J Clin Oncol 2014. 32(5s),(suppl). (abstract # 8585)
"Gene expression analysis of B-cell receptors (BCR) pathway identify PDE4B gene as potential therapeutic target to overcome glucocorticoid resistance in primary CNS lymphoma".
J Clin Oncol 2014. 32 (5s), (suppl). (abstract # 2088)
DNA damage repair proteins (PARP1, ATM, P53) expression and its association with proliferation index and survival in Mantle cell lymphoma.
Modern Pathology. 2014 Feb;27 Suppl 2(Suppl 2): 360A.
“microRNA-223”. High expression correlated with normal cytogeneticsand differentiated morphology in Adult De- Novo Acute Myeloid Leukemia (AML).
Modern Pathology. 2014 Feb;27 Suppl 2(Suppl 2): 333A.
Co-expression of C-myc and Bcl2 proteins in Adult De-Novo Acute Myeloid Leukemia (AML). Correlation with chromosomal changes and survival.
Modern Pathology. 2014 Feb;27 Suppl 2(Suppl 2): 357A.
Flow-Cytometric Detection of Aberrant T-Cell Immunophenotype Accurately Predicts the Presence of Clonal TCR Gene Rearrangements.
Modern Pathology. 2013; 354A (Abstract #1482).
Detection of Minimal Residual Disease (MRD) in B Lymphoblastic Leukemia/Lymphomia (B- ALL) using a 9 Parameter Kaluza Radar Plot.
Modern Pathology. 2013; 343A #1436).
Prognostic Impact of WT1 Protein Expression on Overall Survival in DE- Novo Acute Myeloid Leukemia (AML) with Normal Cytogenetics.
Modern Pathology. 2012; 25(2): 339A (Abstract #1419).
Notch/HES1 and PARP1 Protein Co-Expression among B- Lymphoblastic Leukemia/Lymphoma Patients (pts) Prediacts Good Prognosis.
Modern Pathology. 2012; 25(2): 354A (Abstract #1487).
Significance of P53 Immunostaining in the Diagnosis of Myelodysplastic Syndromes.
Modern Pathology. 2012; 25(2):356A (Abstract #1494).
LMO2 (LIM Domain Only 2, Rhombotin-Like 1) Is Expressed in a Subset of Acute Myeloid Leukemia Patients and Correlated with Normal Cytogenic Status.
Modern Pathology. 2012; 25(2):360A (Abstract #1510).
GCB vs ACB Protein Signature in Mantle Cell Lymphoma (MCL). MUM1 Expression Correlate with Proliferation Index (Ki-67) without Impact on Survival.
Modern Pathology. 2012; 25(2): 383A (Abstract #1604)
Presence of Minimal Residual Disease by Flow Cytometry After Induction Chemotherapy Is Less Predictive of Overall and Progression-Free Survival Compared to Conventional Prognostic Factors Including Cytogenetic Risk and Age.
Blood. Nov 2012; 120 (21): (Abstract #1424).
A miRNA Risk Score for the Prediction of Response tp Lenalidomide in Multiple Myeloma (MM) Patients.
Blood. Nov 2011; 118(21):451 (Abstract #978)
Immune cell subsets in haematopoietic cell transplant recipients associated with GVHD or infections.
Bone Marrow Transplant 46 (Suppl 1):S42, 2011.
High herpesvirus-specific T cell counts are associated with near-zero likelihood of malignancy relapse and a low likelihood of infections due to any pathogen (oral presentation)
Blood. November 2010. Vol 116 (21): (Abstract # 1285)
miRNA Risk Score for the Prediction of Response to Rituximab-CHOP Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma.
Blood. November 2010. Vol 116 ( 21): 324
Oral Session: Bortezomib Induced BRCAness Sensitizes Multiple Myeloma Cells to PARP Inhibitors.
Blood. Nov 2010; 116(19) #789.
Median Channel Fluorescence (MCF) for Transferrin Receptor 1 (CD71) Show Poor Correlation with Ki-67 Staining Pattern and Histological Grade in Follicular Lymphoma (FL).
Modern Pathology. 2010; 23 (1):288A (Abstract #1293).
Differential Expression of PU.1 Protein Among Acute Leukemia Samples as Detected by Immunohistochemistry.
Modern Pathology. 2010; 23 (1):312A (Abstract #1393).
Dysregulated Expression of Transcription Factor PU.1 (Sfpi1) in Pre-B-Cell Acute Lymphoblastic Leukemia/Lymphoma is Associated with Aggressive Clinical Course.
Modern Pathology. 2010; 23 (1): 312A (Abstract #1394).
Wilms’ Tumour Gene (WT1) Protein Expression Pattern is Associated with Adverse Clinical Outcome Among Pre-B-Cell Acute Lymphoblastic Leukemia/Lymphoma (ALL) Patients (pts).
Modern Pathology. 2010; 23 (1): 310A (Abstract #1384).
Multiple and Persistent Atypical NK-cell Lymphoproliferative Lesions in Gastrointestinal (GI) Mucosa Mimicking NK-cell Lymphoma. Clinico-Pathological Features & Follow-Up in a Unique Case Series.
Modern Pathology. 2010; 23 (1): 309A (Abstract #1383)
Interin β7-Mediated Regulation of Multiple Myeloma Cell Adhesion, Migration and Survival.
Blood. 2010; 114 (22): 392 (Abstract #949).
Expression of Integrin Beta 7 (IT[ß]7 Identify a High-Risk Group among Multiple Myeloma (MM) Patients Treated with High Dose Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT).
Modern Pathology. 2009; 22 (1): 276A #1253.
miRNA Expression in Multiple Myeloma as Predictive Model of Response to Bortezomib.
Blood. 2009; 114 (22): (Abstract # 4918).
Among Alpha Thalassemia Patients (pts), Genotypes are Closely Associated With The Degree Of Microcytosis / Mean Corpuscular Volume (MCV) Values.
Modern Pathology. 2009; 22 (1): 269A (Abstract #1224).
Automated Quantitative Proteomic Analysis Platfrom (HISTORX): Clinical Application And Comparison With Routine Immunohistochemistry Among Diffuse Large B-cell Lymphoma (DLBCL) Patients (pts).
Modern Pathology. 2009; 22 (1): 373A (Abstract #1691).
The impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Blood. 2008; 112 (11): 3-1356 (Abstract # 1731).
An Automated and Quantitative Protein Expression-Based Classification System to Identify High Risk Multiple Myeloma Patients.
Blood. 2008; 112 (11): 3-1356 (Abstract # 735).
Validation of a Novel Tissue Array Based Classification of Multiple Myeloma (MM).
Blood. 2008; 112 (11): 3-1356 (Abstract # 1671)
Comparison of CD23 Expression in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Clinical utility of a threshold value in differential diagnosis.
Journal of Hematopathology, 2008; 172 (1).
Cyclin D expression pattern in t(4;14) and FGFR3 positive versus negative multiple myeloma.
Modern Pathology. 2008; 21 (1): 264A (Abstract #1208).
P53 expression combined with Germinal centre B-cell (GCB) phenotype improves risk stratification in aggressive diffuse large B-cell lymphoma (DLBCL) patients (pts) treated with high dose combination chemotherapy followed by Autologous stem cell transplant (ASCT).
Modern Pathology. 2008; 21 (1): 264A (Abstract #1207)
Over expression of cyclin B2 predicts poor clinical outcome among Multiple Myeloma (MM) patients (pts) post autologous stem cell transplant (ASCT).
Modern Pathology. 2008; 21 (1): 264A (Abstract #1206)
Reduced Adverse Effects and Improved Engraftment in the Pediatric Transplant Population upon Dilution of HPC, Cord Blood Products Prior to Infusion.
Blood. 2008; Nov 16; 112 (11): 4137
Lenalidomide overcomes poor prognosis conferred by del13q and t(4;14) but not del17p13 in Multiple Myeloma: Results of the Canadian MM016 trial.
Blood. 2007; 110 (11): 1026 #3597
A Comparison of gating strategies used in the analysis of B-cell Non-Hodgkin’s Lymphomas.
Cytometry. 2007, 72B (6): 488 (Abstract #18).
CD71 Expression as a marker of proliferation in mitogen induced stimulation of T cells.
Cytometry. 2007, 72B (6): 488 (Abstract #17).
A Tissue Microarray classification in Multiple Myeloma (MM) predicts survival post autologous stem cell transplant (ASCT).
Blood. 2007; 110 (11): 138-139 (Abstract #449).
CD4+ T cell immune response predicts survival independently from IPI score among Diffuse Large B-cell Lymphoma (DLBCL) patients.
The Malaysian Jr. of Pathology, 2007; 29 (sup. A): 184 ( Abstract #221).
Correlation of Leukocyte Alkaline Phosphatase (LAP) Score with Philadelphia Chromosome and BCR/ABL Fusion.
Int. Jr. Lab. Hem. 2007. Vol 29 (1): 109 (Abstract #819).
Coexistence of p190 and “aberrant” BCR-ABL1 fusion transcripts among p210+ Chronic Myelogenous Leukemia (CML) patients (pts) are transient and correlate with complex karyotype.
Lab. Investigation. March 2007; 87 (1): 247A (Abstract #1130).
High Affinity IL-2 Receptor (CD25) Expression among Chronic Lymphocytic Leukemia (CLL) Patients is Independent of Mutational Status and ZAP-70 Positivity.
Lab Investigation, March 2007; 87 (1): 244A (Abstract #1118).
Over Expression of Regulator of G-Protein Signalling-1 (RGS1) in Myeloma Cells Result in Decreased Adhesion & Enhanced Migration through MAPK Pathway.
Lab Investigation, March 2007; 87 (1): 251A (Abstract #1151).
Lack of Coexistent t(4;14) or FGFR3 Expression among del 13 Myeloma is Associated with Plasmablastic Morphology.
Lab Investigation, March 2007; 87 (1): 251A (Abstract #1152).
Detection of FGFR3 by Immunohistochemistry in Multiple Myeloma is Highly predictive of t(4;14) by FISH and is associated with CD56 (NCAM1) expression.
Blood. 2006; 108(11): 357b.
Lenalidomide Overcomes Poor Prognosis Conferred by Deletion of Chromosome 13 and t(4;14) in multiple myeloma: MM016 trial.
Blood. 2006; 108 (11): 1016a.
Transmission of a Follicular Lymphoma by Allogeneic Bone Marrow Transplantation – Evidence to Support the Existence of a Lymphoma Progenitor Cell.
Blood. 2006; 108 (11) (Abstract #2415).
Correlation of Flow Cytometric ZAP-70 Results Using a Modified Fixation/Permeabilization Kit with Somatic Hyper Mutation Data.
ISAC XXIII International Congress. 2006: 221.
Clinical Significance of Surface Immunoglobin (sIg) Expression in Diffuse Large B-cell Lymphoma (DLBCL), Is IgM Expression Associated With Aggressive Disease?
Mod Path. 2006. 19 (Suppl 1): 242A.
Value of Blood Cell Chimerism Evaluation in Long Term Post-Transplant Survivors Among AML and ALL.
Mod Path. 2006. 19 (Suppl 1): 235A
Somatic Hypermutation of the Immunoglobulin Heavy Chain (IgH) Gene in Mantle Cell Lymphoma.
Mod Path. 2006. 19 (Suppl 1): 235A.
Cyclin D1- and t (11;14) Positive B-cell Neoplasms Resembling Marginal Zone B-Cell Lymphoma – A Morphologic Variant of Mantle Cell Lymphoma.
Mod Path. 2006. 19 (Suppl 1): 235A
Coagulation testing among patients with high hemotocrit (Hct); Is there a clinical value of anticoagulant / Hct volume ratio adjustment.
Am J Clin Pathol. 2005:124:649, (Abstract #71).
Clinical significance of TIMP1 expression in Diffuse large B-cell lymphoma (DLBCL).
Mod Path. 2004. 17(suppl 1): 258A.
Expression of TIMP4 in non-Hodgkin lymphoma – its association with histological grade and various cytokines.
Mod Path. 2004. 17(suppl 1): 256A.
Lymphoplasmacytic Lymphoma/ Waldenstrom’s Macroglobulinemia (LPL/WM) in bone marrow. Pax- 5 immunostain highlights a vascular-centered tumor growth with variations in cellular composition and architecture in lymphoplasmacytoid, lymphoplasmacytic and polymorphous subtypes.
Mod Path. 2003. 16 (1): 257A.
The clinical significance of cytogenetic findings in Lymphoplasmacytic Lymphoma/ Waldenstrom’s Macroglobulinemia.
Mod Path. 2001; 14 (1): 172A.
Diffuse large B-cell lymphoma occurring in patients with Waldenstrom’s Macroglobulinemia: Clinicopathological features in 11 cases.
Mod Path. 2001; 14 (1): 172A.
Lymphoplasmacytic Lymphoma/ Waldenstrom’s Macroglobulinemia involving extramedullary sites.
Mod Path. 2001; 14 (1): 170A.
Lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia – bone marrow morphology identifies a subset of patients with accelerated clinical course.
Blood. 2000; 96 (supl 2). 278b
Atypical presentation of multiple sclerosis and presence of giant cells- Autopsy findings in a young patient died of pulmonary embolism.
Arch. Anat. Cytol. Path.1998; 46:544(1055).
Expression of metalloproteinases and their inhibitors in various Histologic grade in B-cell lymphomas.
Mod Path. 1997; 10:130A.
TIMP-1 and TIMP-2: Restricted Expression in Normal and Neoplastic Lymphoid Cells.
Tissue Inhibitors of Metalloproteinases in Development and Disease 2000; 79 (6).
Expression of TIMP-1 in Burkitt’s lymphoma cell lines, correlation with aggressive phenotype.
Blood. 1995; 86 (10): 183.
Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases (TIMPs) in Reactive and Neoplastic Lymphoid Cells.
Blood. 1995; 86 (10): 184.
